The Center for Medicare and Medicaid Innovation today announced a new payment model for Medicare Part D and Medicare Advantage drug plans beginning January 2020, which will test new incentives for plans, patients and providers to choose drugs with lower list prices. Plans participating in the voluntary five-year model will take on greater risk for spending in the catastrophic phase of Part D and share in any resulting savings to federal reinsurance subsidy costs. The model also includes a Part D rewards and incentives program and other tools to help plans control drug costs and enrollees choose drugs with lower list prices. Also today, the Centers for Medicare & Medicaid Services announced changes to the MA Value-Based Insurance Design model for calendar year 2020, which will allow plans to provide reduced cost sharing and additional supplemental benefits to enrollees based on condition and/or socioeconomic status; bolster rewards and incentives for beneficiaries to improve their health; and increase access to telehealth services. 
 

Perspective
Public
As we move into the second half of 2026 and Congress returns to work in Washington, D.C., next week, lawmakers face a list of difficult issues that demand…
Headline
Most hospital outreach laboratories have until July 31 to report required private payer clinical diagnostic laboratory data for services furnished during the…
Headline
The Centers for Medicare & Medicaid Services July 2 issued a proposed rule that would increase Medicare hospital outpatient prospective payment system…
Headline
The Centers for Medicare & Medicaid Services July 1 launched the Medicare GLP-1 Bridge, a short-term demonstration program designed to provide eligible…
Headline
A blog by Noah Isserman, AHA director of health insurance and coverage policy, explains why a recent analysis by the Medicare Payment Advisory Commission…
Blog
Public
Medicare Advantage now covers more than half of eligible Medicare beneficiaries, making its impact on hospitals, health systems and patients impossible to…